VCG
RETA

Vantage Consulting Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Vantage Consulting Group’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6
Closed -$1K – 1715
2020
Q4 		$1K Buy
+6
New +$788 ﹤0.01% 1836

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vantage Consulting Group's RETA Position: Q1 2021 in Review

Vantage Consulting Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 6 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in RETA in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

  • Vantage Consulting Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 6 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1K in Q4 2020.
  • 201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.